BioCentury’s roundup of translational innovations also includes new insight into repeat expansion in Huntington’s and 10 new products

Plus: A HilleVax vaccine disappoints, and another TIGIT miss for Genentech

Plus: New data from Wave, G1 and Jazz

Plus: Data from Amgen-AstraZeneca, Biogen-Ionis and more

In partnership with FDA, industry and disease foundations, FNIH is creating a one-stop shop for data on the rare disease to spur diagnostics and therapeutics development 

In ascending to the ranks of surrogate endpoint, NfL stands to galvanize ALS clinical trials and accelerate validation of the next biomarkers

Assessing results from BioCentury’s survey of VCs on the collapse of SVB, and analysis of FDA’s tofersen panel and draft guidance on accelerated approval 

FDA advisory committee backs accelerated approval of Biogen therapy, but rejects full approval

FDA proposing two paths to regulatory flexibility; one would establish NfL as a surrogate endpoint for the disease

18-year veteran of agency a strong advocate for regulatory flexibility as head of Office of Neuroscience